logo
  

Bank Of America Chief Accounting Officer Neil Cotty To Step Down

Bank of America Corp. (BAC) disclosed in a regulatory filing that Neil Cotty will no longer serve as the Corporation's Chief Accounting Officer, effective March 1, 2015. Cotty will continue with the Corporation to assist in Bless's transition.

Rudolf Bless has been appointed the Corporation's Chief Accounting Officer, effective March 1, 2015. Bless joined the Corporation as Deputy Chief Accounting Officer in November 2014. Prior to joining the Corporation, Bless was employed by Credit Suisse Group AG as Chief Accounting Officer from January 2002 to October 2014 and Deputy Chief Financial Officer from October 2010 to October 2014.

The company noted that Charles O. Holliday, Jr. and Clayton Rose, each a member of the board of directors of Bank of America Corporation, each separately informed the Corporation that he would not stand for re-election as a member of the Board at the Corporation's 2015 annual meeting of stockholders.

On February 23, 2015, the Board determined the nominees for election by the Corporation's stockholders at the Annual Meeting. All current directors of the Board, excluding Mr. Holliday and Dr. Rose, have been nominated in accordance with the Corporation's Corporate Governance Guidelines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT